ClinicalTrials.gg
Not yet recruitingNCT07280299Updated Dec 12, 2025

Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease

A Phase 2 interventional study of Low Dose GT-02287 and High Dose GT-02287 in Parkinson Disease, sponsored by Gain Therapeutics, Inc.. Not yet recruiting. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Gain Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.

Read the detailed description

This is a 48-week, double-blind, randomized, placebo-controlled Phase 2a study testing two doses of oral GT-02287 in people with early Parkinson's disease (PD), both treated and untreated.

The study has three parts:

  • Screening Period lasting up to 45 days
  • Treatment Period lasting about 341 days
  • Follow-up Period lasting up to 33 days Participants will have 7 onsite visits for efficacy, safety, tolerability, and biomarker assessments (Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, and a Follow-Up Visit at Week 52). In addition, there will be 5 additional visits for laboratory blood tests (Weeks 2, 16, 20, 30, and 42).

Approximately 111 participants will be randomized into three groups (high dose, low dose, placebo).

Participants can have idiopathic PD or be heterozygous for a pathogenic variant in the GBA1 gene. Participants who have other PD-associated genetic variants (e.g., leucine rich repeat kinase 2 [LRRK2]) are ineligible. All participants will be genotyped to determine their PD-associated genetic status before enrollment.

At the start, participants undergo screening and baseline tests, including motor assessments, quality of life, sensor measurements, and collection of fluid and blood samples for biomarkers. Some baseline tests may be done just before dosing.

The study will measure efficacy through various motor, quality of life, disease progression, non-motor and other symptoms of PD, and cognitive tests, along with wearable sensor data.

Safety will be assessed by recording adverse events, lab tests, vital signs, body weight, heart monitoring, and questionnaires.

The study will also analyze GT-02287 levels in blood and spinal fluid, and its effects on biomarkers.

02

Conditions studied

  • Parkinson Disease

Browse trials for

03

In context

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 111 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Gain Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to provide written and willing to comply with the requirements and restrictions of the study
  • Willing to undergo PD-related genetic testing and analysis
  • Any sex, ≥30 and ≤85 years of age
  • of ≥18 and ≤40 kg/m2 and a body weight of at ≥55 kg and \<120 kg at Screening
  • Diagnosis of PD based on MDS criteria
  • Within 5 years of PD diagnosis
  • Positive SAA in CSF at Baseline
  • Hoehn \& Yahr 1-2.5, inclusive
  • Naïve to pharmacological treatment for PD with no initiation of dopaminergic treatment expected during the first 9 months of the study or on stable PD medication for ≥3 months prior to Screening, including ≥4 weeks at the same dose(s) immediately before Screening with no changes to dose(s), or medication(s) expected during the first 9 months of the study
  • Not pregnant or breastfeeding
  • If participant is either of or produces potentially viable sperm, participant must agree to use 2 forms of (barrier method and a second highly effective form of birth control/contraception, as defined in the protocol) if engaging in potentially reproductive intercourse (with a partner who produces potentially viable sperm or is of childbearing potential, respectively)
  • Agreeing not to participate in another study while taking part in this study

Exclusion criteria

Exclusion Criteria:

  • Other neurological disorders, including but not limited to Alzheimer's disease, amyotrophic lateral sclerosis, frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome, Huntington's disease, multiple system atrophy, dementia with Lewy bodies, secondary (e.g. drug-induced) parkinsonism, multiple sclerosis, or epilepsy
  • PD-associated LRRK2 pathogenic variant or other PD-associated genetic mutations other than GBA1
  • Severe motor fluctuations and/or disabling dyskinesias based on the investigator's clinical assessment
  • Deep-brain stimulation
  • Hallucinations, delusions, or other psychotic symptoms requiring antipsychotic medication Use of dopamine antagonists (antipsychotics) or anticholinergic medications
  • Dementia by clinical diagnosis and/or a score of ≤20 and/or a history of behavioral impairment
  • to GT 02287 or any of its
  • Concomitant medications including drugs metabolized primarily by that have a narrow therapeutic window, substrates of BCRP that have a narrow therapeutic window, strong or moderate inhibitors or strong inducers of CYP3A4 that could affect the metabolism and plasma levels of GT 02287, including herbal supplements and certain foods.
  • Concomitant disease including, but not limited to cardiovascular conditions, diabetes, disease, cancer, active infectious disease, psychotic disorders and symptoms, depressive symptoms, drug and/or alcohol misuse as defined in the protocol
  • abnormalities in laboratory test
  • to lumbar puncture (LP) including current treatment with anticoagulants or any other contraindications that might preclude safe completion of the LP
  • Blood donation >500 mL within 3 months
  • Malabsorption or relevant disorder which may impact the absorption of GT-02287
  • Participation in any interventional clinical study within 3 months or 5 half-lives, whichever is longer, prior to Screening
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (estimated)

Study arms

  • Active comparator
    Low Dose GT-02287

    GT-02287 400 or 600 mg/day

    Drug: Low Dose GT-02287

  • Active comparator
    High Dose GT-02287

    GT-02287 800 or 1000 mg/day

    Drug: High Dose GT-02287

  • Placebo comparator
    Placebo

    Magnesium aluminometasilicate (MAS)

    Drug: Placebo

Interventions

  • DrugLow Dose GT-02287

    Sachets containing 400 mg/day or 600 mg/day of active (GT-02287), depending on the participant's body weight. Each daily dose will be prepared as an oral suspension by mixing the content of 1 sachet with the vehicle (supplied in an amber glass bottle) and the requisite volume of tap water.

    Also known as: GT-02287 400 or 600 mg/day

  • DrugHigh Dose GT-02287

    Sachets containing 800 mg/day or 1000 mg/day of active (GT-02287), depending on the participant's body weight. Each daily dose will be prepared as an oral suspension by mixing the content of 1 sachet with the vehicle (supplied in an amber glass bottle) and the requisite volume of tap water.

    Also known as: GT-02287 800 or 1000 mg/day

  • DrugPlacebo

    Sachets containing 420 to 1200 mg of MAS indistinguishable from the active sachets. Each daily dose will be prepared as an oral suspension by mixing the content of 1 sachet with the vehicle (supplied in an amber glass bottle) and the requisite volume of tap water.

    Also known as: Magnesium aluminometasilicate (MAS)

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 48 in the sum of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score and Part III score [Efficacy]

    Change from Baseline to Week 48 in the sum of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score and Part III score assessed in the practically defined OFF state. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of four parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be rated by the patient and/or caregiver. Part III assesses the motor signs of PD and is rated by the investigator (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. A higher score indicates more severe symptoms of PD.

    Time frame: From baseline to Week 48

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and tolerability]

    Incidence, nature, relationship to investigational product (IP), and severity of adverse events (AEs); Incidence of clinically significant findings for clinical laboratory evaluations, physical and neurological examinations, body weight , vital signs measurements, 12-lead o 12-lead electrocardiograms (ECGs), Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: From baseline to Week 48

  2. Change from Baseline to Week 48 in the MDS-UPDRS Part II score [Effect on motor function]

    Change from Baseline to Week 48 in the MDS-UPDRS Part II score. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of four parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be rated by the patient and/or caregiver. A higher score indicates more severe symptoms of PD.

    Time frame: From baseline to Week 48

  3. Change from Baseline to Week 48 in the MDS-UPDRS Part III score [Effect on motor function]

    Change from Baseline to Week 48 in the MDS-UPDRS Part III score assessed in the practically defined OFF state. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of four parts. Part III assesses the motor signs of PD and is rated by the investigator (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. A higher score indicates more severe symptoms of PD.

    Time frame: From baseline to Week 48

  4. Change from Baseline to Week 48 in the Timed Up and Go (TUG) test [Effect on motor function]

    Change from Baseline to Week 48 in the Timed Up and Go (TUG) test performed in the practically defined OFF state. The TUG is a clinical test for assessing functional mobility and balance, where a person times how long it takes to stand up from a chair, walk 3 meters, turn 180 degrees, walk back, and sit down again. A time of less than 14 to 15 seconds indicates good mobility, while longer times suggest an increased risk of falling, poor physical performance, and potentially neurological issues.

    Time frame: From baseline to Week 48

  5. Change from Baseline to Week 48 in the Parkinson's Disease Questionnaire 39 (PDQ-39) score [Effect on quality of life]

    Change from Baseline to Week 48 in the Parkinson's Disease Questionnaire 39 (PDQ-39) score. The PDQ-39 is a 39-item self-report questionnaire, which assesses PD-specific health-related quality over the last month. The questionnaire measures 39 items, which assess 8 domains of health: mobility (10 items), activities of daily living (6 items), emotional well being (6 items), stigma (4 items), social support (3 items), cognitions (4 items), communication (3 items), and bodily discomfort (3 items). Each item is scored on the following scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, and 4 = always. Items in each subscale and the total scale can be summarized into an index and transformed linearly to a scale from 0 (perfect health as assessed by the measure) to 100 (worst health as assessed by the measure).

    Time frame: From baseline to Week 48

  6. Change from Baseline to Week 48 in the Schwab and England Activities of Daily Living (SEADL) scale [Effect on activities of daily living]

    Change from Baseline to Week 48 in the Schwab and England Activities of Daily Living (SEADL) scale. The SEADL Scale assesses the capabilities of people with impaired mobility in a range of life activities. The scale uses a percentage score to rate a person's abilities, with 100% indicating complete independence (able to do all chores without slowness, difficulty, or impairment) and 0% indicating full dependence (bedridden and almost completely comatose).

    Time frame: From baseline to Week 48

  7. Change from Baseline to Week 48 in the Patient Global Impression Scale - Severity (PGI-S)

    Change from Baseline to Week 48 in the Patient Global Impression Scale - Severity (PGI-S). The PGI-S is a simple, direct, easy to use scales used to rate the response of a condition to a therapy. It is a transition scale for the participant to rate their condition now as compared with how it was prior to before starting the treatment on a scale from 1 "Very much better" to 7 "Very much worse" with lower scores indicating greater improvement.

    Time frame: From baseline to Week 48

  8. Change from Baseline to Week 48 in the Clinical Global Impressions Scale - Severity (CGI-S)

    Change from Baseline to Week 48 in the Clinical Global Impressions Scale - Severity (CGI-S). The CGI-C scale is a clinician-rated measures of severity of a symptom or condition, using a single item, 6-point-scale. The CGI-S scale ranges from 1 ("None") to 6 ("Very Severe") with lower scores indicating lower severity.

    Time frame: From baseline to Week 48

Other outcomes

  1. Change from Baseline to Week 48 in the MDS-UPDRS Part I score [Effect on non-motor symptoms of PD]

    Change from Baseline to Week 48 in the MDS-UPDRS Part I score. The MDS-UPDRS is a multimodal scale consisting of four parts. Part I assesses non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and are assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living to be completed by the participant (Range 0-28). For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. A higher score indicates more severe symptoms of PD.

    Time frame: From baseline to Week 48

  2. Change from Baseline to Week 48 in the Cognitive Summary Score (CSS) [Effect on non-motor symptoms of PD]

    Change from Baseline to Week 48 in the Cognitive Summary Score (CSS). The CSS is a composite score that combines results from several detailed neuropsychological tests into a single, more sensitive measure of cognitive ability. It compares the score to norms to identify deficit in cognitive areas like processing speed, working memory, and verbal memory, and tracks cognitive changes over time. CSS scores can range from 0 to 100. A lower score indicates more significant cognitive impairment.

    Time frame: From baseline to Week 48

  3. Change from Baseline to Week 48 in the Purdue Pegboard Test (PPT) total score

    Change from Baseline to Week 48 in the Purdue Pegboard Test (PPT) total score performed in the practically defined OFF state. The PPT is a standardized test to assess fine and gross motor skills and coordination, commonly used to evaluate manual abilities. It measures the ability to move the arms, hands, and fingers quickly and accurately by placing pegs into a board, both with individual hands and with both hands simultaneously, and in an assembly task. The time and the number of pegs inserted is recorded. A faster time is indicative of a better function, i.e., a higher score (more pegs) signifies better performance.

    Time frame: From baseline to Week 48

  4. Change from Baseline to Week 48 in the Geriatric Depression Scale 15-item version (GDS-15)

    Change from Baseline to Week 48 in the Geriatric Depression Scale 15-item version (GDS-15). The 15-item Geriatric Depression Scale (GDS-15) is a depression screening tool developed for use in older adults. The GDS-15 has a yes-no format. Scores range from 0 to 15; the higher the score the more likely the individual is experiencing depression.

    Time frame: From baseline to Week 48

  5. Change from Baseline to Week 48 in the Movement Disorder Society-Non-motor Scale (MDS-NMS) score

    Change from Baseline to Week 48 in the Movement Disorder Society-Non-motor Scale (MDS-NMS) score. The MDS-NMS is a 52-item rater-administered scale to assess a wide range of non-motor symptoms in Parkinson's disease. It measures both frequency (0/never to 4/ \>51% of the time) and severity (0/not present to 4/major distress or disturbance) of 13 domains (depression, anxiety, apathy, psychosis, impulse control/related disorders, cognition, orthostatic hypotension, urinary, sexual, gastrointestinal, sleep/wakefulness, pain, and other). Each question is scored by multiplying frequency x severity. All question scores for each domain are summed, and the scores for each domain are summed to provide the Total Score (range = 0-832) with the higher score indicating greater non-motor symptom burden. The higher the total score, the more progressed (i.e., worse) is the disease state.

    Time frame: From baseline to Week 48

  6. Change from Baseline to Week 48 in Neuronal Synuclein Disease (NSD) stage

    Change from Baseline to Week 48 in Neuronal Synuclein Disease (NSD) stage. The NSD41 is a research framework that classifies the stages of diseases like PD by combining biological markers and functional impairment. It uses a 7-stage system, beginning with Stage 0 for a genetic variant and progressing through stages based on the presence of abnormal α synuclein protein, dopaminergic dysfunction, and the increasing severity of functional impairment in later stages. Higher stages are indicative of more severe functional impairment.

    Time frame: From baseline to Week 48

  7. Number of participants who require an increase in, or initiation of, dopaminergic treatment

    Number of participants who require an increase in, or initiation of, dopaminergic treatment by Week 48.

    Time frame: From baseline to Week 48

  8. Change from Baseline to Week 48 in the University of Pennsylvania Smell Identification Test (UPSIT) [Olfaction]

    Change from Baseline to Week 48 in in olfaction as measured with the University of Pennsylvania Smell Identification Test (UPSIT) The UPSIT is considered to be an reliable and accurate tool for diagnosing smell loss and screening for conditions like PD. The test is a 40-item, self-administered "scratch-and-sniff" test to quantitatively measure olfactory function. The test involves scratching a strip to release an odor and selecting the correct identification from multiple-choice options. The UPSIT has a minimum score of 0 and maximum score of 40 with lower scores indicating a greater degree of impairment.

    Time frame: From baseline to Week 48

  9. Mean trough plasma levels of GT-02287

    Mean concentration of GT-02287 24 hours postdose, immediately before the next dose

    Time frame: From baseline to Week 48

  10. Mean peak plasma levels of GT-02287

    Mean concentration of GT-02287 around Cmax/time to maximum concentration (Tmax)

    Time frame: From baseline to Week 48

  11. Mean CSF levels of GT-02287 at Week 48

    Postdose (approximately 4 hours postdose) concentration of GT-02287 in CSF at Week 48

    Time frame: Week 48

  12. Changes in mechanistic and disease biomarkers

    Change in biomarkers in biofluids (CSF, blood, plasma) from Baseline to Week 48

    Time frame: From baseline to Week 48

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jun 2028, 25 months later.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 25 months is above that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 12, 2025
StartEst.
May 30, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07280299
Lead sponsor
Gain Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
May 30, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Dec 12, 2025

Study contacts

Gain Therapeutics Clinical Operations
Contact
info@gaintherapeutics.com
+41919211131
Jonas Hannestad, CMO
study director · Gain Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion